Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...175176177178179180181182183184185...10651066»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A backpack-based myeloid cell therapy for multiple sclerosis. (Pubmed Central) -  Apr 23, 2023   
    We developed monocyte-adhered microparticles ("backpacks") for activating myeloid cell phenotype to an anti-inflammatory state through localized interleukin-4 and dexamethasone signals...Backpack-carrying monocytes conferred therapeutic benefit in EAE mice, as quantified by improved motor function. The use of backpack-laden monocytes offers an antigen-free, biomaterial-based approach to precisely tune cell phenotype in
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Retrospective data, Journal:  Efficacy and safety of intravenous glucocorticoid therapy for IgG4-related ophthalmic disease. (Pubmed Central) -  Apr 23, 2023   
    As a first-line treatment for IgG4-ROD, IV glucocorticoid therapy was well-tolerated, led to better clinical remission and more effectively prevented inflammatory relapse than oral steroids. Further research is needed to establish guidelines on dosage regimens.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Journal:  Ixazomib - lenalidomide - dexamethason in heavily pretreated multiple myeloma patients - case reports. (Pubmed Central) -  Apr 23, 2023   
    In addition, a literature review was conducted to summarize the key characteristics of paediatric FUMHD cases. Repeated treatment with a combination of proteasome inhibitors (ixazomib) and immunomodulatory drugs (lenalidomide) may lead to significant clinical benefit in some patients and should be considered even in end-stage disease patients.
  • ||||||||||  AAV8-VRC07 / National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Systemic Administration and Transient Immunosuppression Eliminate Anti-Drug Antibody Responses Following Vectored Immunoprophylaxis in Mice (Board No. 1595) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1934;    
    A more recent Phase I study (VRC603) has demonstrated that administration of AAV8-VRC07 results in long-term systemic expression of VRC07 in humans for up to three years...Finally, we assessed the effect of two immune-suppressing drugs, dexamethasone, and cyclosporine, in inhibiting the ADA response and bNAb expression following VIP and found that dexamethasone, but not cyclosporine, inhibited ADA responses and increased antibody expression in the C57BL/6 mouse model...Importantly, the route of AAV administration had a significant influence on ADA response and bNAb expression. Our results also highlight the feasibility of reducing ADA through transient immunosuppression using dexamethasone.
  • ||||||||||  dexamethasone / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
    Improved In Vivo Hemophilia A Gene Therapy Based on A Novel Immune-Escape Lentiviral Vector System (Board No. 1266) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1916;    
    These early results demonstrated that iv 4711-LV-VEC-299 without chemo-conditioning in the F8 knockout mice was feasible and exhibited high and long-lasting coagulation function and immune evasion. The novel 4711-LV system could be a potentially safe, convenient and effective HA gene therapy tool in clinical applications.
  • ||||||||||  dexamethasone / Generic mfg.
    Intrathecal Lentiviral Gene Therapy to Treat X-linked Adrenoleukodystrophy Disease (Board No. 1414) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1830;    
    The i.t. injection of LV-GFP ABCD1 demonstrated transgene biodistribution throughout the CNS as well as the PB and spinal cord in vivo. Further characterization of ABCD1 expression and phenotype correction of i.t. LV-ABCD1injection in the dl3/9ABCD1 KO mice will be presented.
  • ||||||||||  dexamethasone / Generic mfg.
    Improved Transgene Expression from GenY AAV Serotype Vectors in Human Cells In Vitro and in Murine Hepatocytes In Vivo (Board No. 1281) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1742;    
    As can be seen in Figure 1D, GenY AAV6 vectors also mediated up to ~3-fold increase in transgene expression in HeLa cells compared with the WT AAV6 vectors, and it further increased by ~3-fold following dexamethasone-treatment. Since glucocor-ticoids, such as predni-solone, are routinely used prophylactically to mitigate the AAV vector-mediated host immune responses in clinical trials, our data suggest that insertion of the full-length GRE site in the recombinant AAV genomes may be a simple strategy to achieve increased trans-gene expression at lower doses of AAV vectors.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Immune Responses Observed to AAV Gene Therapy for the Treatment of GM2 Gangliosides (Room 411) -  Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1716;    
    Patients were treated with an immunosuppressive regimen that included rituximab, corticosteroids (3 months post-delivery) and sirolimus (6 months post-delivery)...The patient was treated with solumedrol at 10mg/kg/day for three days and resulting T-cell responses and transaminases resolved...None of the other cytokines measured including IFN?, IL-4, MCP-1, IL-8, IL-2, IL-1?, TNF?, IL-17A, IL12p70, TGF?, IL-10 or IL-6 or were significantly changed. Taken together, despite the delivery route and substantial immunosuppression regimen, notable immune responses, including T and B-cell responses to AAV capsid, were observed in all patients after CNS targeted AAV gene therapy.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Clinical-MRI Dissociation in Spinal Cord Sarcoidosis: A Case Report. (A5) -  Apr 21, 2023 - Abstract #EAN2023EAN_2370;    
    On admission, a longitudinally extensive T2-hyperintense lesion (A), associated with patchy gadolinium enhancement (B). The spinal cord lesion resolved nearly completely after treatment with corticosteroids (C).
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Copper deficiency related myelopathy (A5) -  Apr 21, 2023 - Abstract #EAN2023EAN_2365;    
    Serum copper levels should be checked early in the investigation of non-compressive myelopathy. Zinc containing denture cream affects copper absorption and can deplete serum copper levels.
  • ||||||||||  methylprednisolone oral / Generic mfg.
    Presenting the Post-Corona-Virus Immune Treatment trial (PoCoVIT)  (B2) -  Apr 21, 2023 - Abstract #EAN2023EAN_1007;    
    418 participants will be allocated 1:1 to 4 weeks of 1mg/kg bodyweight oral methylprednisolone (followed by 14d tapering) or placebo... These findings will provide information on treatment strategies for PCS and potentially enable greater insights into the underlying pathophysiological mechanisms of the syndrome.
  • ||||||||||  aspirin / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    Juvenile arterial ischemic stroke due to focal cerebral arteriopathy: a case-based approach. (A3) -  Apr 21, 2023 - Abstract #EAN2023EAN_974;    
    Predictive markers of recurrence and outcome, such as FCASS, are on-going validation. Use of steroid with or without antiviral therapy (hypothetical post-infectious pathophysiology) are commonly used although lack of interventional trial results.
  • ||||||||||  prednisone delayed-release tablet / Generic mfg.
    Journal:  Accuracy in body composition scanning by adult half-body DXA scanning. (Pubmed Central) -  Apr 21, 2023   
    No abstract available HBS scanning by DXA evidenced agreement, and high values of accuracy and precision to assess body composition indicators (BMC, FM, LST and %FM).
  • ||||||||||  dexamethasone / Generic mfg., paracetamol / Generic mfg., celecoxib oral / Generic mfg.
    Journal:  Repeat dose steroid in high pain responders after total knee arthroplasty - A study protocol. (Pubmed Central) -  Apr 21, 2023   
    HBS scanning by DXA evidenced agreement, and high values of accuracy and precision to assess body composition indicators (BMC, FM, LST and %FM). The data from this study will provide evidence for the effect of a repeated dose of dexamethasone as an analgesic adjuvant in patients undergoing total knee arthroplasty with a high risk of postoperative pain.
  • ||||||||||  Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories
    Enrollment open, Trial completion date, Trial primary completion date:  IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) -  Apr 21, 2023   
    P3,  N=272, Recruiting, 
    Learning Points/ Administration of ceftazidime avibactam appears to be well tolerated and effective in pediatric with PDR K. pneumonia infection. Not yet recruiting --> Recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Apr 2025
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial completion date, Trial primary completion date:  PTSD Prevention Using Oral Hydrocortisone (clinicaltrials.gov) -  Apr 20, 2023   
    P2,  N=220, Recruiting, 
    Trial completion date: Jul 2023 --> Dec 2023 | Initiation date: Jan 2023 --> May 2023 | Trial primary completion date: Jun 2023 --> Nov 2023 Trial completion date: May 2025 --> Apr 2024 | Trial primary completion date: May 2025 --> Apr 2024
  • ||||||||||  Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, budesonide/formoterol (PT009) / AstraZeneca
    Trial completion date, Trial primary completion date:  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (clinicaltrials.gov) -  Apr 20, 2023   
    P3,  N=2200, Recruiting, 
    Trial completion date: May 2025 --> Apr 2024 | Trial primary completion date: May 2025 --> Apr 2024 Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
  • ||||||||||  epinephrine / Generic mfg.
    Enrollment change, Trial completion date, Trial primary completion date, Surgery:  FESS: Functional Endoscopic Sinus Surgery Study (clinicaltrials.gov) -  Apr 20, 2023   
    P1/2,  N=80, Recruiting, 
    Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025 N=40 --> 80 | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
  • ||||||||||  dexamethasone / Generic mfg., dexmedetomidine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Surgery:  Ultrasound Guided Rectus Sheath Block and Transversus Abdominis Plane Block (clinicaltrials.gov) -  Apr 20, 2023   
    P=N/A,  N=90, Completed, 
    Phase classification: P4 --> P2 Not yet recruiting --> Completed | N=60 --> 90 | Trial completion date: Aug 2022 --> Jan 2023
  • ||||||||||  bortezomib / Generic mfg., lenalidomide / Generic mfg.
    Trial completion date, Trial primary completion date:  DETERMINATION: Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (clinicaltrials.gov) -  Apr 19, 2023   
    P3,  N=660, Active, not recruiting, 
    The addition of magnesium sulfate to the analgesic cocktail for PIA can prolong postoperative analgesia, decrease the consumption of opioids, and effectively alleviate early postoperative pain after TKA. Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Feb 2022 --> Jun 2022